Phase II Study of Antineoplastons A10 and AS2-1 in Children Wtih Brain Tumors
OBJECTIVES:
- Determine the antitumor activity of antineoplastons A10 and AS2-1 in children with
brain tumors by determining the proportion of patients who experience an objective
tumor response.
- Evaluate the adverse effects of and tolerance to this regimen in these children.
OUTLINE: This is an open-label study.
Patients receive gradually escalating doses of intravenous antineoplaston A10 and
antineoplaston AS2-1 6 times daily until the maximum tolerated dose is reached. Treatment
continues for at least 2 months in the absence of disease progression or unacceptable
toxicity. Patients achieving stable disease may continue treatment.
Tumors are measured every 8 weeks for 2 years, every 3 months for the third and fourth
years, every 6 months for the fifth and sixth years, and then annually thereafter.
PROJECTED ACCRUAL: A total of 20-40 patients will be accrued for this study.
Interventional
Masking: Open Label, Primary Purpose: Treatment
Response rate based on tumor measurements taken at 12 weeks
No
Stanislaw R. Burzynski, MD, PhD
Study Chair
Burzynski Research Institute
Unspecified
CDR0000066490
NCT00003458
September 1996
Name | Location |
---|---|
Burzynski Clinic | Houston, Texas 77055-6330 |